It's a little bit premature to be declaring victory until we've had a large enough number of clinical trials and enough people treated for long periods of time to understand the risk-to-benefit ratio better.
My overall reaction is that I'm pleased, because we need the data.
Lipids are strong predictors of heart disease; CRP is a strong predictor of heart disease, and these predictors are independent of one another.
But there's still almost 30 percent of patients in a recent survey that weren't getting aspirin during an acute heart attack.
Basic research has shown that in the arteries in the heart, that inflammatory processes that are reflected by higher levels of CRP may play a role in the development of hardening of the arteries or atherosclerosis.
My colleagues and I were quite surprised that the FDA has taken such an extreme position.
Copyright © 2024 Electric Goat Media. All Rights Reserved.